Meta-Analysis
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Feb 28, 2021; 9(1): 74-87
Published online Feb 28, 2021. doi: 10.13105/wjma.v9.i1.74
Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis
Tejas Kamleshbhai Patel, Parvati B Patel, Manish Barvaliya, Vijayalaxmi, Hira Lal Bhalla
Tejas Kamleshbhai Patel, Vijayalaxmi, Hira Lal Bhalla, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur 273008, Uttar Pradesh, India
Parvati B Patel, Department of Pharmacology, GMERS Medical College, Gotri, Vadodara 390021, Gujarat, India
Manish Barvaliya, Department of Pharmacology, Government Medical College, Bhavnagar, Bhavnagar 364001, Gujarat, India
Author contributions: All authors designed the meta-analysis; Patel TK and Patel PB conducted the literature search; Patel TK and Barvaliya M extracted the data; Patel TK, Patel PB and Barvaliya M analyzed the data; all authors interpreted the data; Patel TK wrote the first draft and revised subsequent drafts with input from Patel PB, Barvaliya M, Vijayalaxmi, and Bhalla HL.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
PRISMA 2009 Checklist statement: Study has been conducted as per the PRISMA 2009 checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tejas Kamleshbhai Patel, MD, Associate Professor, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Kunraghat, Gorakhpur 273008, Uttar Pradesh, India. dr.tkp2006@yahoo.co.in
Received: November 12, 2020
Peer-review started: November 12, 2020
First decision: February 12, 2021
Revised: February 16, 2021
Accepted: February 25, 2021
Article in press: February 25, 2021
Published online: February 28, 2021
Processing time: 110 Days and 5.2 Hours
Core Tip

Core Tip: Remdesivir is an antiviral drug having in vitro and in vivo activity against severe acute respiratory syndrome coronavirus 2. United States Food and Drug Administration has granted emergency use authorization for its use in all hospitalized patients. The findings of this meta-analysis suggest remdesivir can enhance clinical recovery without having significant benefits on mortality outcomes. because of lack of any major safety concerns, its use is recommended in the absence of effective antiviral drugs against coronavirus disease 2019.